(¿Â¶óÀÎ) 2021³âµµ ´ëÇÑÀÓ»ó¹Ì»ý¹°ÇÐȸ Á¦24Â÷ Çмú´ëȸ (2ÀÏÂ÷) : 2021-07-02±³À°ÀÏÀÚ : 2021-07-02
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) 2021³âµµ ´ëÇÑÀÓ»ó¹Ì»ý¹°ÇÐȸ Á¦24Â÷ Çмú´ëȸ (2ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÀÓ»ó¹Ì»ý¹°ÇÐȸ
´ã´çÀÚ : ÀÌÇѳª
¿¬¶ôó : 02-401-1570
À̸ÞÀÏ :
kscm.office@gmail.com ±³À°Á¾·ù : Áø´Ü°Ë»çÀÇÇаú¹Ì»ý¹°ÇÐ
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 14 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 250,000¿ø
ºñ°í Á¤È¸¿ø 10¸¸¿ø, ÁØȸ¿ø 5¸¸¿ø, ´Üüȸ¿ø 10¸¸¿ø, ºñȸ¿ø 25¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 07:30~08:30 ME1: Troubleshooting of SARS-CoV2 Real Time RT-PCR ¼ºÈï¼·(¿ï»êÀÇ´ë)
ÈÞ½Ä 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 08:30~09:00 Break/exhibition ()
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 09:00~10:00 Oral Presentation I ()
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 10:00~11:00 Oral Presentation II ()
ÈÞ½Ä 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 11:00~11:10 Break/exhibition ()
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 11:10~12:00 Surveillance by Objectives (SBO): an old but precious concept for fighting antimicrobial resistance (AMR) in Korea Mark Miller(McGill University)
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 12:00~12:30 Updates in diagnosis of drug-resistant tuberculosis ±èâ±â(¼¿ïÀÇ°úÇבּ¸¼Ò)
ÈÞ½Ä 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 13:00~13:30 Clinical application of NGS for SARS-CoV-2 or X À̱âÇö(õ·¦¹ÙÀÌ¿À)
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 13:30~14:00 Building laboratory capacity for Pandemic X ÀÌÇõ¹Î(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 14:00~14:30 Emerging infectious diseases other than SARS-CoV2 ÀÌÁ¾À±(ºÎ»êÀÇ´ë)
ÈÞ½Ä 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 14:30~14:50 Break/exhibition ()
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 14:50~15:20 Periodic preemptive screening method of SARS-CoV-2 for healthcare workers À̾ç¼ø(ÇѾçÀÇ´ë)
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 15:20~15:50 Application of rapid diagnostics on preemptive screening of carbapenemase-producing Enterobacteriales Á¤Çý¼±(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 15:50~16:20 Preoperative search and destroy for Staphylococcus aureus surgical site infections ÀåÁ¤Çö(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 07:30~08:30 ME2: Troubleshooting of Antimicrobial Susceptibility Testing ¹ÚÁ¤¼ö(¼¿ïÀÇ´ë)
ÈÞ½Ä 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 08:30~09:00 Break/exhibition ()
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 09:00~09:30 Past & future of the GLASS Á¤Åë·É(WHO)
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 09:30~10:00 AMR national action plan & KOR-GLASS ÃÖÁرæ(Áúº´°ü¸®Ã»)
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 10:00~10:30 Burden of major AMR pathogens causing bloodstream infections ±èµµ±Õ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 10:30~11:00 Current AMR status of Acinetobacter baumannii & emerging colistin resistance ±è¿µ¾Æ(±¹¹Î°Ç°º¸Çè°ø´Ü Àϻ꺴¿ø)
ÈÞ½Ä 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 11:00~11:10 Break/exhibition ()
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 11:10~12:00 Surveillance by Objectives (SBO): an old but precious concept for fighting antimicrobial resistance (AMR) in Korea Mark Miller(McGill University)
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 12:00~12:30 COVID-19: What We Thought We Knew, What We Think We Know, and What We Don¡¯t Know Norman Moore(Abbott)
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 13:00~13:30 Accelerated diagnostics for infectious diseases based on culture or non-culture ¹Ú¿¬ÁØ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 13:30~14:00 Rapid detection of antimicrobial resistance ÃÖ±ÔÅÂ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 14:00~14:30 Clinical implication of metagenomics ¿ëµ¿Àº(¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 14:30~14:50 Break/exhibition ()
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 14:50~15:20 Application of MALDI-TOF in clinical microbiology ¿À¿¹Áø(³ì½ÊÀÚ)
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 15:20~15:50 How handy is an Isothermal amplification kit? ¹è¹ÌÇö(ÇѾçÀÇ´ë)
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 15:50~16:20 Good or bad lateral flow immunoassay Á¤Àç¿ì(µ¿±¹ÀÇ´ë)